Imugene股票(IMU.AX)今日盘中重挫，一度暴跌18.8%至0.345澳元，创下7月2日以来新低；最终收跌11.8%，报0.375澳元。这家制药公司通过配售获得坚定承诺，融资2250万澳元(约1468万美元)。每股0.33澳元的发行价较7月11日收盘价折价22.4%，突显了市场对折价融资的负面反应。公司还计划通过股票购买计划额外融资1500万澳元，发行价相同。所得资金将用于推动azer-cel项目，包括2026年的关键临床试验等。Azer-cel是一种同种异体CAR T细胞疗法，专为治疗复发或难治性弥漫性大B细胞淋巴瘤设计。今日交易量激增至170万股，是30天平均水平的2.9倍。年内迄今，该股已暴跌70.2%，计入今日跌幅。(汇率：1美元=1.5328澳元)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.